Pablo García-Díaz

Nov 1, 2024 | jitc.bmj.com | Ahmed Gad |Jessica Morris |Pablo García-Díaz |Lea Godret-Miertschin

http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.

Oct 19, 2023 | cell.com | Pablo García-Díaz

Highlights Synthetic transcription factors (synTFs) that are inducible by exogenous or autonomous inputs are useful in cell and gene therapy for temporal and dosage control of the expression of beneficial transgenes. Recent progress in engineering DNA-binding domains (DBDs) and transcriptional activation domains (TADs) composed primarily of human sequences reduces concerns about the immunogenicity of synTF components.